Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Table 2 Incidence of adverse events in 44 patients with cirrhosis and hepatocellular carcinoma undergoing treatment with sorafenib n (%)

Adverse events	Statistics
Fatigue	29 (65.9)
Grade 1	11 (25.0)
Grade 2	11 (25.0)
Grade 3	7 (15.9)
Bleeding	7 (15.9)
Grade 1	3 (6.8)
Grade 2	1 (2.3)
Grade 3	3 (6.8)
Hand-foot syndrome	14 (31.8)
Grade 1	7 (15.9)
Grade 2	7 (15.9)
Grade 3	0 (0.0)
Diarrhea	15 (34.1)
Grade 1	6 (13.6)
Grade 2	8 (18.2)
Grade 3	1 (2.3)
Hepatic grade 31AEs	8 (18.2)
Other AEs2	20 (45.5)

¹An increase in aminotranspherase and bilirubin after starting sorafenib was observed in all patients;

²Including rash, hypertension, alopecia, diabetes, mucositis, abdominal pain, voice changes. All grades were evaluated according to Common Terminology Criteria for Adverse Event version 3.0. AEs: Adverse events.